Leap Therapeutics (LPTX) vs. Its Peers Head-To-Head Survey

Leap Therapeutics (NASDAQ:LPTX) is one of 452 public companies in the “Pharmaceutical Preparations” industry, but how does it contrast to its peers? We will compare Leap Therapeutics to similar businesses based on the strength of its valuation, analyst recommendations, earnings, dividends, risk, profitability and institutional ownership.

Analyst Ratings

This is a summary of recent ratings for Leap Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Leap Therapeutics	1	0	0	0	1.00
Leap Therapeutics Competitors	4808	9968	16008	372	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 110.45%. Given Leap Therapeutics’ peers stronger consensus rating and higher possible upside, analysts clearly believe Leap Therapeutics has less favorable growth aspects than its peers.

Valuation and Earnings

This table compares Leap Therapeutics and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Leap Therapeutics	N/A	-$67.56 million	-1.68
Leap Therapeutics Competitors	$440.95 million	-$69.10 million	-10.22

Leap Therapeutics’ peers have higher revenue, but lower earnings than Leap Therapeutics. Leap Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Leap Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Leap Therapeutics	N/A	-247.44%	-146.51%
Leap Therapeutics Competitors	-2,625.49%	-359.57%	-43.35%

Risk & Volatility

Leap Therapeutics has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500. Comparatively, Leap Therapeutics’ peers have a beta of 10.21, suggesting that their average share price is 921% more volatile than the S&P 500.

Insider & Institutional Ownership

30.5% of Leap Therapeutics shares are owned by institutional investors. Comparatively, 39.4% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 4.3% of Leap Therapeutics shares are owned by company insiders. Comparatively, 13.9% of shares of all “Pharmaceutical Preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Leap Therapeutics peers beat Leap Therapeutics on 9 of the 13 factors compared.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.